drugset / Trial / NCT00140712

Ropinirole Tablets In Young Patients With Restless Legs Syndrome

NCT00140712

Phase 1 Completed 9 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a two-period dose rising study of Ropinirole Immediate Release in adolescent patients with restless legs syndrome (RLS) in order to determine the starting dose for the ropinirole titration regimen for this age group. Patients will receive two single doses unless poor tolerability is observed following the first dose.

Timeline

Start
2005-06-10
Primary completion
2008-02-28
Completion
2008-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropinirole Small molecule 0.25 mg